PRVL · Prevail Therapeutics
Acquired Company
Lilly completed the acquisition of Prevail Therapeutics Inc. on January 22, 2021 for $22.50 per share in cash plus one non-tradable CVR worth up to $4.00 per share.
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$23.00
Open
$23.00
Volume
N/A
Day Range
$23.00 - $23.00
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
N/A
Institutional Own.
N/A
Qtr Updated
Sep 30th 2024